True North Therapeutics
A pioneering biotechnology company selectively inhibiting the Complement pathway for diseases of high unmet clinical need.
Launch date
Employees
Market cap
-
Enterprise valuation
€364m (Public information from May 2017)
San Francisco California (HQ)
| Date | Investors | Amount | Round |
|---|---|---|---|
$22.0m | Series A | ||
$35.0m | Series B | ||
$40.0m | Series C | ||
$45.0m | Series D | ||
$400m Valuation: $400m | Acquisition | ||
N/A | - | ||
| Total Funding | €129m | ||